P I Industries Ltd Q4 FY2026 Concall Summary

Key Takeaways

• AgChem exports still under pressure: Revenue declined on lower volumes as the global crop protection downcycle persisted, compounded by Middle East disruption and a shift to just-in-time purchasing.
• Pharma delivered 40% full-year growth: The CRDMO platform is scaling, but the segment remains pre-EBITDA-positive and management sees a multi-year build before it reaches a J-curve inflection.
• Gross margin expanded despite the top-line drag: Favourable product mix and operational efficiencies offset pricing corrections and raw material volatility, with new molecules now 18% of AgChem exports.
• The first homegrown NCE is launching: Pioxaniliprole, discovered in India, is expected in markets this year, marking a shift from contract manufacturer to global innovator.
• What to watch next quarter: Whether the promised H2 export recovery materializes, the pace of domestic demand pickup in Kharif, and any further pricing or volume deterioration in the largest CSM molecule.

AgChem Export Environment

• Multi-year downcycle continues: The global crop protection market remains in contraction, with recovery uneven across geographies and further complicated by the Middle East conflict since late February.
• Just-in-time purchasing: Customer buying behaviour has shifted toward shorter-cycle, need-based ordering, which depresses volume visibility and makes quarter-to-quarter forecasting harder.
• Volume-led revenue decline: The export revenue drop was primarily driven by lower volumes reflecting the broader industry contraction and customer delivery schedules, not a single large program loss.
• Pricing corrections add pressure: Realizations declined roughly 5%, which management attributed to product mix, R&D deflation and some pricing correction, but declined to give a straight answer on the split.
• Volume over margin: Management is prioritizing holding market share and volume through the trough, betting that margins return when the cycle swings.

Mayank Singhal: "Our focus today would be to continue to hold the market share and volume because the margins could always return back when the market swings."

New Molecules & Innovation Pipeline

• New molecules now 18% of AgChem exports: This contribution, up from prior periods, reflects a deliberate derisking strategy and innovation-led approach even as overall export revenues declined.
• New molecules growing faster than the portfolio: While total revenues fell due to external challenges, new molecules have been shaping well and contributing incrementally to the margin profile.
• Five new molecules commercialized in FY26: The company continues to convert its R&D pipeline into commercial products despite the difficult demand environment.
• First NCE, Pioxaniliprole, launching in FY27: Discovered in India, this is the first homegrown new chemical entity coming to market, with global filing applications expected at end of FY27 or FY28 and strategic partnerships being explored.
• Biologicals gaining regulatory traction: A nematode product received US regulatory approval, the first-ever new biological nematode at scale in that market, and is already launched in Brazil and Mexico with sales expected to more than triple in Brazil this year.

Mayank Singhal: "I do not think a single company from India has done that and it is probably the first company in any chemical sector to do that. So, that is the benchmark of putting our capability to take from discovery to markets."

Pharma & Diversification

• Pharma revenue grew 40% for the full year: The platform is onboarding strategic customers and building differentiated CRDMO capabilities, though from a relatively small base.
• EBITDA-positive still a couple of years away: Management estimates the segment needs a ₹500–600 crore top line to reach positive EBITDA, which could take two to three years given the long gestation of pharma CDMO products.
• CDMO follows a J-curve: Products in pharma typically take five to six years from discovery to impactful manufacturing revenue, so near-term investments will precede the revenue inflection.
• Electronic chemicals pipeline advancing: Four to five products are in development with a target of roughly \$80–100 million in revenue over the next five to six years, backed by approximately ₹500 crore in investment.
• Global biologicals break-even expected in a couple of years: Technology and product performance show strong acceptance, but the agri sector depression has slowed the expected growth rate.

Mayank Singhal: "If you completely understand CRDMO, a product does not get into a manufacturing play in pharma at least for five to six years for impactful numbers."

Domestic Business

• Muted near-term demand: Elevated channel inventory, lower crop prices and incessant rainfall have suppressed domestic agrochemical offtake despite fundamentally encouraging agri conditions and good Rabi acreages.
• Four new products launched: Three herbicides and one insecticide were introduced in the domestic brands portfolio during the year.
• Kharif season expected to revive momentum: Management anticipates stronger growth as the Kharif season unfolds, supported by new brand launches and the upcoming Pioxaniliprole introduction.
• Biological portfolio facing regulatory transition delays: The shift in the biological product portfolio has encountered regulatory timeline slippages, adding to the domestic demand softness.

Margins & Financials

• Gross margin expanded: Favourable product mix and strong operational efficiencies supported expansion despite the revenue decline, pricing corrections and raw material volatility.
• New molecules accretive to margins: The growing share of new molecules in the portfolio is incrementally improving the margin profile even as legacy products face pricing pressure.
• Capex deployed for multi-year ramp-up: Asset investments span capacities, technology, NCEs and new business arenas with longer gestation, and management noted ramp-up typically takes four to five years.
• Contract assets to remain rangebound: Expected to hover around ₹500–700 crore given the current business model and structures, with quarter-to-quarter shifts possible.
• ETR to inch up to 24%: Management guided that the effective tax rate will rise to 24% in FY27 and thereafter.
• Gross margin target: Management aims to maintain the average gross margin of the prior year.

Mayank Singhal: "I cannot give you a straight answer because nobody seems to have a straight answer in this very volatile market."

Leadership & Organizational Change

• Rajnish Sarna steps down as JMD: He has relinquished executive responsibilities, including investor relations, to focus on his health, while continuing as a Non-Executive Director on the Board.
• Group CFO to lead investor engagement: Sanjay Agarwal will actively engage with the investor community going forward, ensuring continuity in communication and strategic engagement.
• SAP S/4 Hana implemented: The successful go-live marks a key milestone in the company's digital transformation journey.
• Strategic repositioning underway: Management framed the shift as moving from distributor to global-scale manufacturer to global innovator, with partnerships across the value chain as the backbone.

Mayank Singhal: "We believe this brings a major shift in the PI way from distributor to global scale manufacturer to reposition as a global innovator with the backbone strength of partnerships across the value chain."

Guidance & Commitments

Key Metrics